We are experiencing 4 week turn-around time in review of submissions and resubmissions. We recommend commencing this process concurrently with your ethics submission and allowing at least 8 weeks for registration to be completed from date of first submission. We currently do not have the capacity to expedite reviews.

Note also there are delays to review of updates. We appreciate your patience.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT02940691

Registration number
Ethics application status
Date submitted
Date registered
Date last updated

Titles & IDs
Public title
Scale-up of Treatment of Hepatitis C Infection Among People Who Inject Drugs
Scientific title
A Phase IV, Open-label, Single Arm, Multicentre Trial of Grazoprevir/Elbasvir for Genotype 1 or 4 in People With Chronic Hepatitis C Virus Infection and Recent Injecting Drug Use or Receiving Opioid Substitution Therapy
Secondary ID [1] 0 0
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Hepatitis C 0 0
Condition category
Condition code
Infection 0 0 0 0
Other infectious diseases
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

Study type
Description of intervention(s) / exposure
Treatment: Drugs - Grazoprevir/elbasvir

Experimental: Grazoprevir/elbasvir - Grazoprevir/elbasvir (100mg/50mg) daily taken orally for 12 weeks.

Treatment: Drugs: Grazoprevir/elbasvir
Grazoprevir/elbasvir (100mg/50mg) once daily for 12 weeks.

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Primary outcome [1] 0 0
Undetectable HCV RNA at 12 Weeks Post End of Treatment (SVR12) - Number with undetectable HCV RNA at 12 weeks post end of treatment (SVR12) following 12 weeks of daily grazoprevir/elbasvir (100mg/50mg)
Timepoint [1] 0 0
12 weeks post treatment
Secondary outcome [1] 0 0
Number of Participants With Treatment Completion - Number who completed HCV treatment as prescribed (12 weeks of grazoprevir/elbasvir (100mg/50mg) daily)
Timepoint [1] 0 0
12 weeks from treatment administration
Secondary outcome [2] 0 0
End of Treatment Response (Negative HCV RNA at the End of Treatment) - Number with undetectable HCV RNA at end of treatment following 12 weeks of daily Grazoprevir/Elbasvir (100mg/50mg)
Timepoint [2] 0 0
12 weeks from treatment administration

Key inclusion criteria
- Participants have voluntarily signed the informed consent form.

- Be =18 years of age on day of signing informed consent form.

- Have chronic HCV genotype 1 or 4 infection (defined as detectable HCV RNA).

- Recent injecting drug use (previous 6 months) or receiving opioid substitution

- HIV-1 infected subjects enrolled in the study must meet the following criteria:

- Have HIV infection documented by any licensed rapid HIV test or HIV enzyme or
chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry
(Baseline) and confirmed by a licensed Western blot or a second antibody test by
a method other than the initial rapid HIV and/or E/CIA, or by HIV-1 p24 antigen,
or plasma HIV-1 RNA viral load

- b) Be on HIV Antiretroviral Therapy (ART) for at least 4 weeks prior to study
entry using an ART regimen that is allowable with the intended DAA regimen as
determined by the current PI and the Liverpool drug interaction website
(http://www.hiv-druginteractions.org/) or current prescribing guidelines for
elbasvir/grazoprevir OR be naive to treatment with any antiretroviral therapy
(ART) with a baseline CD4 count of >200 and have no plans to initiate ART
treatment while participating in this study and through to at least Follow-up
Week 4.

- Negative pregnancy test at screening and baseline (females of childbearing potential

- All fertile males and females must be using effective contraception during treatment
and during 14 days after treatment end.
Minimum age
18 Years
Maximum age
No limit
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
- Is taking or plans to take any prohibited medications as per DAA Product Information
or herbal supplements, including but not limited to St. John's Wort (Hypericum
perforatum) within 2 weeks of Baseline.

- Is currently using or intends to use barbiturates.

- Is a female and is pregnant or breast-feeding, or expecting to conceive or donate eggs
from Baseline and continue throughout treatment, and after the last dose of study
medication (as per the regimen requirements), or longer if dictated by local

- Has any condition or pre-study laboratory abnormality, ECG abnormality or history of
any illness, which, in the opinion of the investigator, might confound the results of
the study or pose additional risk in administering the study drugs to the subject.

- Had a life-threatening SAE during the screening period.

- Has exclusionary laboratory values as listed below:

- Haemoglobin < 9.5 g/dL for both males and females

- Platelets < 50 x 10^3 /µL

- Serum albumin < 3.0 g/dL

- Patients with Child Pugh-B or C decompensated cirrhosis

- Previous HCV treatment-experience.

- Ongoing severe psychiatric disease as judged by the treating physician.

- Frequent injecting drug use that is judged by the treating physician to compromise
treatment safety.

- Inability or unwillingness to provide informed consent or abide by the requirements of
the study.

- Is Hepatitis B surface antigen (HBsAg) positive

NOTE: Sanger sequencing will be performed on a pre-treatment sample on all participants.

Study design
Purpose of the study
Allocation to intervention
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?

Intervention assignment
Single group
Other design features
Phase 4
Type of endpoint(s)
Statistical methods / analysis

Recruitment status
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Kirketon Road Centre - Darlinghurst
Recruitment hospital [2] 0 0
St Vincent's Hospital - Darlinghurst
Recruitment hospital [3] 0 0
The Langton Centre - Darlinghurst
Recruitment hospital [4] 0 0
Nepean Hospital - Kingswood
Recruitment hospital [5] 0 0
Drug and Alcohol Clinical Services (Hunter) - Newcastle
Recruitment postcode(s) [1] 0 0
2010 - Darlinghurst
Recruitment postcode(s) [2] 0 0
2751 - Kingswood
Recruitment postcode(s) [3] 0 0
2300 - Newcastle

Funding & Sponsors
Primary sponsor type
Kirby Institute

Ethics approval
Ethics application status

Brief summary
This study is a phase IV, open-label, single arm, multicentre study whose aim is to assess
whether interferon-free and ribavirin-free Direct Acting Antiviral (DAA) Hepatitis C Virus
(HCV) therapy with grazoprevir/elbasvir, will be feasible for the treatment of People who
inject drugs (PWID) with recent injecting drug use or people receiving opioid substitution
therapy and chronic HCV genotype 1 or 4 infection.
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 0 0
Greg Dore, MBBS
Address 0 0
Kirby Institute
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
For IPD and results data, please see https://clinicaltrials.gov/show/NCT02940691